Geneos Wealth Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $143K | Sell |
2,721
-191
| -7% | -$10.1K | ﹤0.01% | 1099 |
|
|
2026
Q1 | $161K | Buy |
2,912
+4
| +0.1% | +$217 | ﹤0.01% | 1028 |
|
|
2025
Q4 | $143K | Buy |
2,908
+4
| +0.1% | +$187 | ﹤0.01% | 1043 |
|
|
2025
Q3 | $125K | Sell |
2,904
-2,792
| -49% | -$109K | ﹤0.01% | 1049 |
|
|
2025
Q2 | $219K | Sell |
5,696
-6,716
| -54% | -$257K | 0.01% | 957 |
|
|
2025
Q1 | $481K | Buy |
12,412
+8,120
| +189% | +$297K | 0.01% | 903 |
|
|
2024
Q4 | $145K | Buy |
+4,292
| New | +$155K | 0.01% | 948 |
|
|
2022
Q3 | – | Sell |
-22,010
| Closed | -$1.2M | – | 2254 |
|
|
2022
Q2 | $1.2M | Buy |
22,010
+230
| +1% | +$12.7K | 0.06% | 281 |
|
|
2022
Q1 | $1.19M | Sell |
21,780
-208
| -0.9% | -$11.3K | 0.05% | 312 |
|
|
2021
Q4 | $1.21M | Sell |
21,988
-172
| -0.8% | -$8.95K | 0.05% | 349 |
|
|
2021
Q3 | $1.06M | Buy |
22,160
+179
| +0.8% | +$8.99K | 0.04% | 369 |
|
|
2021
Q2 | $1.11M | Sell |
21,981
-1,615
| -7% | -$77.6K | 0.04% | 335 |
|
|
2021
Q1 | $1.1M | Buy |
23,596
+1,286
| +6% | +$58.4K | 0.03% | 400 |
|
|
2020
Q4 | $996K | Buy |
22,310
+1,012
| +5% | +$46.5K | 0.04% | 351 |
|
|
2020
Q3 | $1.01M | Sell |
21,298
-1,064
| -5% | -$53.3K | 0.05% | 287 |
|
|
2020
Q2 | $1.13M | Buy |
22,362
+8,863
| +66% | +$455K | 0.06% | 267 |
|
|
2020
Q1 | $614K | Sell |
13,499
-720
| -5% | -$38.4K | 0.04% | 342 |
|
|
2019
Q4 | $840K | Buy |
14,219
+35
| +0.2% | +$1.95K | 0.04% | 331 |
|
|
2019
Q3 | $750K | Buy |
14,184
+268
| +2% | +$13.8K | 0.04% | 324 |
|
|
2019
Q2 | $696K | Sell |
13,916
-201
| -1% | -$10.1K | 0.04% | 339 |
|
|
2019
Q1 | $737K | Buy |
14,117
+440
| +3% | +$22K | 0.05% | 324 |
|
|
2018
Q4 | $652K | Buy |
13,677
+2,838
| +26% | +$140K | 0.05% | 318 |
|
|
2018
Q3 | $544K | Buy |
10,839
+1,509
| +16% | +$76.7K | 0.04% | 367 |
|
|
2018
Q2 | $470K | Buy |
9,330
+176
| +2% | +$8.86K | 0.04% | 337 |
|
|
2018
Q1 | $447K | Sell |
9,154
-262
| -3% | -$12.2K | 0.04% | 329 |
|
|
2017
Q4 | $417K | Sell |
9,416
-380
| -4% | -$17.6K | 0.04% | 352 |
|
|
2017
Q3 | $497K | Sell |
9,796
-189
| -2% | -$9.59K | 0.05% | 301 |
|
|
2017
Q2 | $538K | Sell |
9,985
-57
| -0.6% | -$3.04K | 0.06% | 276 |
|
|
2017
Q1 | $529K | Sell |
10,042
-4,573
| -31% | -$232K | 0.06% | 261 |
|
|
2016
Q4 | $703K | Buy |
14,615
+8,863
| +154% | +$438K | 0.09% | 201 |
|
|
2016
Q3 | $310K | Buy |
5,752
+663
| +13% | +$36.4K | 0.04% | 348 |
|
|
2016
Q2 | $274K | Sell |
5,089
-1,348
| -21% | -$71K | 0.04% | 366 |
|
|
2016
Q1 | $324K | Buy |
+6,437
| New | +$321K | 0.05% | 320 |
|
Other funds holding GSK
JEST
Geneos Wealth Management's GSK Position: Q2 2026 in Review
Geneos Wealth Management reduced its GSK (GSK) stake by 6.6% in Q2 2026, selling an estimated $10.1K and leaving 2,721 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.
Geneos Wealth Management first reported a position in GSK in Q1 2016 and has held it in 33 quarters since. The position peaked at $1.21M in Q4 2021. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Geneos Wealth Management held 2,721 shares of GSK worth $143K as of Q2 2026.
- Geneos Wealth Management sold 191 GSK shares in Q2 2026, an estimated $10.1K.
- GSK made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1099 holding.
- Geneos Wealth Management first reported a position in GSK in Q1 2016 and has held it in 33 quarters since.
- Geneos Wealth Management's GSK position peaked at $1.21M in Q4 2021.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.